摘要
目的：调查糖尿病并高血压患者的临床治疗要点及现状，并对氨氯地平联合厄贝沙坦的药用价值作出研究。方法：研究经讨论后于2021年2月-2023年3月实行，在内科现有病例信息中遴选出60份，且所属信息的诊疗结果均为糖尿病并高血压，结合双盲法原则对信息予以组别匹配，研究组、对照组为该研究内执行比较的组别，组内对应的治疗措施分为氨氯地平联合厄贝沙坦、常规治疗，比较项目以指标变化、不良症状。结果：研究组在过程中对相关指标的阶段性控制效用、治疗后安全指数评分，均高于对照组，组内统计差异性明显（P＜0.05）。结论：氨氯
Abstract
Objective: To investigate the clinical treatment of patients with diabetes mellitus and hypertension, and to study the medicinal value of amlodipine combined with irbesartan.How: After discussion, the study will be carried out from February 2021 to March 2023.60 cases were selected from the existing medical information, and the diagnosis and treatment results of the information were all diabetes and hypertension, and the information was matched by groups based on the principle of double-blind method.The study group and the control group were the groups for comparison in this study.The corresponding treatment measures in the group were divided into amlodipine combined with irbesartan and conventional treatment, and the index changes and adverse symptoms were compared.Results: The stage control effect and post-treatment safety index scores of the study group were higher than those of the control group, and the statistical difference within the group was significant (P<0.05).Conclusion: The correct administration of amlodipine and irbesartan under supervision can effectively control blood glucose and blood pressure index, which is suitable for clinical treatment.
万方数据